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 ABSTRACT 
BACKGROUND: Functional dyspepsia (FD) is defined by as the presence of 
symptoms thought to originate from the gastroduodenal region. According to Rome III 
criteria the main symptoms of functional dyspepsia include postprandial fullness, early 
satiation, epigastralgia and epigastric burning .In spite of several therapeutic options 
for the treatment of  FD, It can be still confusing to healthcare providers because 
there is no definite treatment for functional dyspepsia. It is necessary to identify the 
better therapeutic options for functional dyspepsia. This study assessed the therapeutic 
outcome and quality of life of patients with functional dyspepsia by treating with 
proton pump inhibitor, domperidone and  acotiamide, and  also the efficacy of 
acotiamide against the other therapeutic options . 
METHOD: It was a prospective study conducted on KMCH  Hospital,Coimbatore in 
which a total 60 patients, were divided into three groups. Patients were divided into 
three groups.(GroupI-Acotiamide+PPI,Group II-Domperidone+PPI,Group III-PPI). 
Patients details were collected from data collection form and symptom analysis carried 
out using Visual Analogue Scale.Quality of life of patients was assessed by using 
Nepean Dyspepsia Index(SF-NDI) questionnaire. The paired   student ‘t’ test was 
conducted to analyze the difference in score after each group of treatment and also to 
assess the efficacy of acotiamide were studies using SPSSv20.0. 
RESULTS: By this study it was found that the overall symptom score was reduced in 
acotiamide and domperidone therapy.(p<0.001 and p= 0.042).While in PPI the overall 
symptom was not significantly  reduced. Overall SF-NDI score showed a significant 
greater improvement from baseline (p=0.000), Similarly all the five SF-NDI subscale 
scores showed  improvement than other two groups. There is significant improvement 
in the abdominal bloating, postprandial fullness, abdominal pain, excessive belching, 
heart burn, upper abdominal discomfort. 
CONCLUSION: Cases with functional dyspepsia have characteristics of middle 
age,male predominance, Non vegetarian food consumers are more prone to develop 
FD. From this study it  was concluded  that  acotiamide  has better efficacy than  PPI 
monotherapy ,and combination of PPI and domperidone therapy. 
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1.  INTRODUCTION 
                Dyspepsia is a term derived from a Greek word “dys” (bad), 
“pepsis”(Digestion) which means bad digestion1. Functional dyspepsia is a disorder 
thought to originate from upper part of gastrointestinal tract. It occurs in general 
population and is a  highly prevalent condition with major socioeconomic and health 
care impact2. There are two types of dyspepsia. Investigated and uninvestigated 
dyspepsia. Investigated dyspepsia or organic dyspepsia is with organic or metabolic 
cause and involves peptic ulcer disease, Gastroesophageal reflux disease (GERD) 
with or without esophagitis, malignancy, pancreaticobiliary disease, uses of certain 
types of drug and H. pylori gastritis. Uninvestigated dyspepsia or functional dyspepsia 
develops in the absence of systemic, organic and metabolic disease.3 
 
COMMON SIGN AND SYMPTOMS 4, 5 
 Postprandial fullness 
 Early satiation 
 Epigastric pain 
 Abdominal bloating 
 Abdominal belching 
 Nausea   
 Vomiting  

 Heart burn.  
 
RISK FACTORS 
Various risk factors have been found to have associated with dyspepsia, they 
are. 
 Helicobacter pylori (H-pylori) infection. 
 Psychiatric disorders 
 Behavioral changes4 
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                The Rome III criteria distinguishes functional dyspepsia from other 
structural disorders. Based on Rome III consensus, FD is subdivided into two 
categories postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS), 
characterised by postprandial fullness and early satiation. It is also referred as meal 
related FD. Epigastric pain syndrome shows symptoms of epigastric pain and burning 
sensation.6 
              Approximately 20-30% patients are affected with FD in general population. 
The pathophysiology of functional dyspepsia is unknown, because of its 
heterogeneous nature. Different management approaches are needed for different  
patients with distinct underlying pathophysiologies. Genetic factors is one of the 
reason for individuals to develop functional gastro intestinal  disorders, environment 
factors and patient attitude and behavior also play a important role in developing 
functional disorder, psychological disorders like patients stress also leads to 
functional dyspepsia.1,4 
Table 1 
 Pathophysiologically relevant factors 
Motility disorder  Unbalanced  volume distribution in 
the stomach. 
 Low volume uptake in drinking 
test 
 Antral hypomotility and reduced 
antral migratory motor complexes. 
 Uncoordinated antroduodenal 
motility 
 Increased postprandial duodenal 
motility. 
 Impaired volume accommodation 
of the fundus 
Sensorimotor disorders  Reduced excitability of enteric 
nerves in the duodenum. 
 Decrease in Parasympathetic tonus 
 Increase in Acid sensitivity in the 
duodenum 
 Increased Fat sensitivity in the 
duodenum associated with 
improved CCK sensitivity. 
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Visceral hypersensitivity  Increased Sensitivity after stomach 
expansion (on an empty stomach 
and after a meal) 
 Increased Sensitivity after 
duodenal, jejunal, and rectal 
expansion 
Immune activation  Increased GDNF, eosinophilic 
granulocytes and macrophages in 
duodenal mucosal biopsy samples 
 Increased degranulation of the 
eosinophilic granulocytes in the 
duodenum 
 TH2-mediated response in the 
duodenum 
 Increased GDNF and NGF 
expression in the H. pylori-positive 
gastric mucosa 
Dysfunctional intestinal barrier  Increased Permeability in the 
proximal small intestine 
Genetic predisposition  Increase in GNβ3-TT genotype 
(increased signal transduction 
between receptor and target 
protein) 
 Decrease in CCK-A receptor CC 
genotype 
Biopsychosocial factors  Anxiety, depression. Increased 
Experience of abuse, stressful life 
events 
 Decrease in  Functional 
connectivity of brain regions 
Altered microbiota  Increase  Prevotella 
 Helicobacter pylori 
Pathophysiology of functional dyspepsia1 
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DIGNOSTIC INVESTIGATIONS OF DYSPEPSIA                        
                Patients with dyspepsia who undergo upper GI investigation and have 
pathological finding may be responsible for the symptoms, such as peptic ulcer, are 
categorized as having organic dyspepsia 5. Upper GI endoscopy is essential to 
investigate the FD patients and there by to excluding other structural diseases, before 
diagnosis of FD upper endoscopy with biopsies and laboratory tests were performed 
in order to exclude the infections, peptic ulceration, celiac disease and neoplasia7.  
                Uncontrolled functional dyspepsia affects very weakly the quality of life of 
patients and social expenses.5 The quality of life (QOL) in FD patients is known to be 
impaired due to symptoms causing emotional distress, problems with food and drink, 
and impaired vitality8. 
 
TREATMENT  
          The treatment of FD is confusing to health care providers, currently there is no 
definite treatment for FD. Wide range of therapies are available for the management 
of functional dyspepsia. H pylori is the main cause of peptic ulcer disease but its role 
in non-ulcer dyspepsia is not well known. It is important that physicians be able to 
recognize dyspepsia, investigations and diagnostic tests and recommend effective 
treatment in order to avoid possible adverse drug reactions and to improve the quality 
of life of patients.9, 10  
 Acid suppressive drugs 
 Helicobacter pylori eradication treatment 
 Antidepressant 
 Psycotherapy. 
 Prokinetics 
 Acid Suppressive Drugs 
              In patients major symptoms of gastrointestinal disorders, acid suppressive 
therapy is mainly used. Proton Pump inhibitors showing 10-15 %  improving 
symptoms for FD patients.6 
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Proton Pump Inhibitors (PPIs) 
                  Patients with FD, mainly those with epigastric pain syndrome proton pump 
inhibitors (PPIs) or histamine type 2-receptor antagonists (H2 blockers) seems to be 
suppress the gastric acid secretion and relieves the epigastric pain or burning. The 
initial gastric acid emptying play a pathogenetic role on symptom generation through 
early onset of duodenal brake, so acid suppression might be successful. Proton pump 
inhibitor (PPI) are the strongest drug for gastric acid suppression .PPI will block 
gastric acid secretion by blocking H+ ion secretion from the parietal cells. They have 
few adverse effect and are well tolerated by for long term- use. Inhibitors of acid 
secretion are therefore prescribed for world wide. Although treatment with acid 
suppression produces symptom relief in a proportion of patients with FD. Retention of 
PPIs in the stomach for longer time may results in an impaired suppression. 
Omeprazole is a highly effective PPI which inhibit gastric acid secretion by blocking 
H+/K+-adenosine triphosphatase in parietal cells.11-13 
 
H. pylori Eradication Therapy 
            Helicobacter pylori infection is the main cause of gastritis, gastroduodenal 
ulcers  and other gastrointestinal disorders. The first line of treatment for H pylori 
eradication consists of proton pump inhibitor (PPI) or ranitidine bismuth citrate, with 
any two antibiotics among amoxicilline, clarithromycin and metronidazole given for 
7-14 days. H. pylori is the most common cause of chronic bacterial infection in 
humans. 20 to 90%, of population include this infection depending on conditions of 
development and hygiene.  The prevalence of H. pylori infection in patients with FD 
varies from 30 to 70%. It is known that H. pylori can cause dyspeptic symptoms, 
inducing motor disorders, causing visceral hypersensitivity, acid secretion alterations, 
active and persistent inflammation.14,15 
 
Antideppressant 
 Tricyclic antidepressants showed beneficial effect from the symptoms of FD. 
The mechanism of action of antidepressants is not clearly understood for 
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gastrointestinal disorders, although there is some evidence that the drugs affect gastric 
sensitivity.  Serotonin/noradrenalin reuptake inhibitor such as venlafaxine failed to 
show any beneficial effect in FD. While Paroxetine, a selective serotonin reuptake 
inhibitor (SSRI), enhanced gastric accommodation .16 
 
Psychotherapy 
          Interpersonal psychotherapy may be effective in FD patients. The prevalence of 
psychiatric symptom is high among FD patients. So improvement of these symptoms 
following psychotherapy in functional gastrointestinal disorders appears to be related 
with reduced psychological distress and improved health condition.17 
   
Prokinetics                 
          Prokinetics are the medications used for enhancing gastric motility acting 
through  receptor. It acts by increasing esophageal sphincter pressure, enhancing 
esophageal peristalsis, gastric emptying and bowel movement 16. 
 
Domperidone 
           Domperidone, is peripheral dopamine D2 antagonist ,blocking dopamine in the 
enteric nervous system, It acts centrally in the chemoreceptor trigger zone, thus by 
reducing the nausea and ,It also effects  motor function and thus improves the gastric 
emptying and peristaltic movement of intestine. So domperidone acts as an antiemetic 
and prokinetic agent. Domperidone had a good safety profile and is treated for FD. It 
is also used as a therapeutic option for variety of GI motility disorders such as 
gastroparesis and gastrooesophagal reflux disorder. But domperidone shown several 
adverse effect such as increase plasma prolactin level on long term treatment .It does 
not cross the blood –brain barrier and a lower cardiovascular risk while having good 
clinical efficacy.  
 
                Omeprazole and domperidone given in combination did not  have any 
clinically relevant pharmacokinetic interactions. Combination therapy of PPI and 
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prokinetics increases symptomatic relief  from FD than PPI monotherapy. It may 
improve patient quality of life.18,12 
Acotiamide 
 Acotiamide is a novel prokinetic agent, it has various pharmacological effects 
on the gastrointestinal tract. which inhibits acetyl choline esterase and exerts its 
gastroprokinetic activity by enhancement of acetylcholine release. Acotiamide is a 
muscarinic receptor antagonist in the enteric nervous system. It blocks M1 and M2 
receptor that alter acetylcholine release. Acotiamide was shown to improve dyspepsia 
symptoms by increasing both gastric accommodation and delayed gastric emptying. It 
relieves both symptoms of epigastric pain syndrome and postprandial distress 
syndrome. Acotiamide also inhibit stress related hormones. Acotiamide modulates 
upper gastrointestinal movement to improve abdominal symptoms resulting from 
hypomotility. 19, 20                                                                            
             This drug was first launched in Japan in June 2013 as a therapeutic agent for 
FD. A phase III trial was done in Europe, and a phase II trial was finished in USA. 
Acotiamide have ability to alter the expression of stress related genes such as GABA 
and neuromedin U in medulla oblongata or hypothalamus. So there by acotiamide has 
an important role in the regulation of stress through the hypothalamic-pituitary-
adrenocortical activity. The dose of acotiamide 100mg three times a day shown a 
overall improvement in the symptoms without any significant adverse events.21 
             Prokinetic therapy has been found to have a positive effect on functional 
dyspepsia but is still not conclusive. The present study will also assess the efficacy of 
acotiamide against the other therapeutic options for FD. 
           This study will assess the therapeutic outcome and quality of life of patients 
with functional dyspepsia who are on any one of the following treatment options --- 
proton pump inhibitor, domperidone and the prokinetic agent acotiamide, and thereby 
compare the three to predict efficacy.  
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2. REVIEW OF LITERATURE 
 
 Ibnu Fajariyadi Hantoro  et al (2018); Conducted a study to determine the 
contribution of clinical, psychosocial, and demographic factors in affected functional 
dyspepsia patients in Indonesia. 124  patients  were enrolled in the study,  HRQoL 
was measured using the Medical Outcomes Study Short-Form 36 (SF-36) physical 
component summary (PCS) and mental component summary (MCS) . The factors 
investigated were age, gender, symptom severity, education level, employment status, 
anxiety, depression, and ethnicity. The Results supported that all domains of HRQoL 
except vitality were impaired in patients with functional dyspepsia. From this study it 
was concluded that there was significant HRQoL impairment in patients with 
functional dyspepsia in Indonesia.[22] 
 
 Varsha Narayanan  et al (2018); carried out a study  on 314  FD patients with meal-
related-symptoms, received acotiamide 100 mg thrice daily for 4 weeks. Improvement 
of the symptoms were evaluated by a questionnaire, as well as tolerance to treatment. 
The results supported that complete relief or significant improvement from 
postprandial fullness, upper abdominal bloating and early satiety was achieved. Mild 
adverse events were reported by 6% patients; mainly headache, nausea, vomiting, 
vertigo, burning sensation, palpitation, and epigastric pain. From this study it was 
concluded  that  acotiamide  improved the meal related FD symptoms with good 
safety profile.[23] 
 
 Young Li et al (2018); conducted a study to evaluate sleep quality and mood 
symptoms in FD, assessing association of FD severity ,disordered sleep, 
psychological symptoms.115 patients were enrolled in this study .sleep disorder was 
assessed by Pittsburgh sleep quality index(PSQI),and symptom checklist-90-reviced 
(SCL-90R) was used to determine depression, anxiety and epigastric pain syndrome. 
The results suggests that lower educational level ,and sleep disturbance were 
independently associated with FD. This study found that FD was associated with 
sleep disorder and psychological therapies may help to reduce FD symptoms[24] 
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.
  
 Agneta Uusijarvi et al (2018); Performed a study to validate Rome III criteria and 
alarm symptom and their ability to distinguish between organic and functional 
dyspepsia. 258 children’s aged 4-17 years with gastrointestinal complaints, and who 
consulted for secondary or tertiary care in Stockholm were enrolled in the study. 
Data’s were collected by using questionnaire on pediatric gastrointestinal symptom 
Rome III. The results supported that 16% having organic disorders 54% having pain 
predominant functional gastrointestinal disorder and 30% having other functional 
diseases .From this study it was concluded that combining the Rome III criteria and 
absence of alarm symptoms from patient questionnaire had high specificity  
           but low sensitivity.[25] 
 

 Satoshi schinozaki et al (2017); Carried out a study based on adherence to an 
acotiamide  improves long term outcomes in patients with functional dyspepsia. 79 
patients with functional dyspepsia were enrolled in the study who underwent 
esophagogastroduodenoscopy. Symptoms and  followed for more than one year.  
Symptom severity assessed by using the lzmo scale and analysed by using Kaplan-
Meier method. The study concluded that recurrence of functional dyspepsia for long 
term is in higher rate. While adherence towards acotiamide decreases the rate of 
reappearance of dyspeptic symptoms.[26] 
 
 J. Tack et al (2017);  Conducted  an open-label safety trial  to evaluate the long-term 
safety and efficacy of  acotiamide on PDS symptoms. Patients  (defined by ROME III 
criteria) aged ≥18 years with active PDS symptoms were enrolled to receive 100 mg  
acotiamide three times daily for 1 year .Patients safety and efficacy of acotiamide was 
monitored by  using the validated LPDS, quality of life using SF-36 and SF-NDI 
questionnaires, and work productivity using WPAI.  The study concluded  that  
acotiamide has  the long-term safety in treatment of FD, and also a remarkable  
change for PDS symptoms, QOL, and work productivity was suggested [8].  
 

 Rasmirekha Behera et al (2017); Conducted a study to assess the efficacy and 
Safety of  Acotiamide  and  Levosulpiride in Functional Dyspepsia . 60 patients were 
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selected for the study. Patients were divided into 2 groups. Group A received 100mg  
acotiamide TDS before meal for 8wks.Group B received levosulpiride 25 mg TDS for 
8 wks. Treatment outcome categorized as excellent: Complete relief of symptoms, 
Good: improvement with only occasional symptoms, nil: no improvement. The result 
supported that the Patients treated with Acotiamide showed more improvement in 
symptoms of FD and better tolerated in comparison to Levosulpiride. This  study 
concluded  that  the Acotiamide found to be quiet safe and effective drug in patients 
of Functional Dyspepsia in comparison to Levosulpiride.[27] 
 

 KY Marakhouski et al (2017); Done randomized controlled, phase 4 study, to 
compare the efficacy and safety of omeprazole-domperidone combination with 
omeprazole monotherapy in gastroesophageal reflux disease (GERD).60 patients were 
enrolled in this study they received  group 1 (omeprazole20 mg+domperidone 30 mg) 
or group 2 (omeprazole 20 mg) in an equal ratio; 2 capsules daily in the morning were 
administered for 8 weeks. Symptom severity was assessed by visual analogue scale 
(VAS) and GERD-Q questionnaire. The study concluded that Omeprazole-
domperidone combination was more effective than omeprazole alone. [12] 
 

 Basha Ayele et al (2017); Done a study to determine the contributing factors for 
dyspepsia at Yirga cheffe primary hospital, southern Ethopia.168 patients were 
enrolled in the study, face to face interview was taken to assess the contributing factor 
for the infection. The result supported that helicobacter pylori infection was six times 
associated with dyspeptic patients than non-Dyspeptic individuals. anxiety and 
depression was six and three times more likely associated with dyspepsia, dyspepsia 
was greater among male, and peaked in the age groups of 21-30 years old, patients 
who consume foods containing peppercorn, who depend on untapped drinking water 
sources, smoking habit, chewing khat. This study concluded that early diagnosis of H. 
pylori ,psychological treatment of patients and food habit of the individuals should 
give attention to prevent and control dyspepsia.[5] 
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
 Young Joo Yang et al (2017) ; Performed a randamised controlled trials (RCTs) of   
prokinetics for treatment of FD. In total 25 RCTs 4473 patients were included  who 
were treated with 6 different prokinetics. Symptoms score was analysed by odds ratio. 
Beysian net work analysis was performed for this study. Study suggests that 
metoclopromide, trimebutein, mosapride, and domperidone showed better efficacy for 
FD treatment than acotiamide and or itopride [28] 
 

 Tareq Al Saadi et al (2016): Performed a study to estimate the epidemiologic 
characteristics and possible risk factors for UD, IBS, and GERD among students at 
Damascus University, Damascus, Syria. 302 valid participants were  enrolled in the 
study. The results supported that  prevalence for UD, IBS, and GERD was 25%, 17%, 
and 16%, respectively. Symptom overlap was present in 46 students (15%), with UD+ 
IBS in 28 (9.3%), UD + GERD in 26 (8.6%), and IBS + GERD in 14 (4.6%) students. 
Eleven (3.6%) students had symptoms of UD +IBS+GERD. From this study it was 
concluded that  risk factors for these disorders remain poorly characterized and need 
further investigations.[29] 
 

 Hiroyuki Osawa et al (2016); Conducted a study  to assess effect of acotiamide in 
patients with functional dyspepsia.51 patients were enrolled in study who treated with 
acotiamide and followed them for more than one year. Patients quality of life and 
symptom severity was assessed by using the Izumo scale.The results supported that 
acotiamide showed a greater improvement on epigastric syndrome (EPS) and 
postprandial distress syndrome(PDS).From this study it was concluded that  
acotiamide treatment improves and resolves EPS symptoms and PDS symptom take 
more longer to resolve than EPS symptoms.[30] 
 

 R Bitwayiki et al (2015); Performed  a cross sectional survey on prevalence of 
dyspepsia       and impact of quality of life among Rwandan healthcare 
workers(HCWs). Quality of patients was assessed by using questionnaires, including 
short of dyspeptic symptoms, and short term Nepean dyspepsia index(SF-NDI). In 
this study 378 enrolled HCWs all of whom provided response to SF-LDQ and 356 
whom responded to SF-NDI.  The results showed that tension and eating/drinking 
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subdomain of the SF-NDI had more effects. This study suggested  that  the prevalence 
of dyspepsia among HCWs in Rwanda is a high and associated with lowered quality 
of life.[31] 
 

 Hiroshi yamawaki et al (2014); Conducted a study  on Twenty-five functional 
dyspepsia (FD) patients were treated with acotiamide (300mg/day) for 4 weeks. 
Anxiety was evaluated using STAI-state/-trait. ACTH and cortisol levels measured in 
FD patients. Acotiamide treatment significantly improved postprandial fullness and 
early satiety in 4 weeks treatment in FD patients compared to those in pretreatment. 
Acotiamide did not affect anxiety using STAI-state/-trait as well as  ACTH and 
cortisol levels in FD patients. This study suggested that further studies is needed for 
more clarification of improvement of FD symptoms in acotiamide  therapy.[32] 
 

 Shuhei mayanagi et al (2014); Done a study to evaluate the efficacy of an initial PPI 
followed by a combination therapy and PPI and acotiamide.105 patients were enrolled  
who started an initial PPI. 23 patients with residual symptoms receives 100mg   
acotiamide three times a day with esomeprazole as a combination therapy for 2 
weeks. The symptoms were evaluated using the modified frequency scale (mFSSG) 
almost all FD related symptoms improved after combination therapy with an 
improvement in the mFSSG Score. The findings suggest that the combination therapy 
of acotiamide and PPI may be effective in selected FD patients as compared with an 
initial PPI therapy.[33] 
 

 Hiroshi Kaneko et al (2014); Performed a study to providing awareness of functional 
dyspepsia and Rome criteria among Japanese internist.1623 subjects were internist 
,1660 were doctors,4264 attendees were enrolled .self administering questionnaire 
were used for data collection. The results supported that existence of Rome criteria 
was known in 39.9% of internist. from this study it was concluded that awareness was 
needed for the medical medical term FD in Japan and revision of Rome criteria for 
routine clinical practice.[34] 
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
 Chatchai Kriengkirakul et al (2012); Conducted a study to evaluate the efficiency of  
proton pump inhibitor (PPI) treatment on patients with overlapping non-erosive 
gastroesophageal reflux disease (NERD) and functional dyspepsia (FD).60 patients 
were enrolled in the study who were underwent treatment of rabeprazole 20 mg b.i.d. 
for 2 weeks. The symptoms were evaluated using a symptom questionnaire with 4-
point Likert scales before and after treatment. The result supported after the PPI 
treatment, epigastric burning, acid regurgitation, heartburn, nausea, vomiting and 
chest discomfort scores were significantly improved compared to pretreatment values, 
whereas postprandial abdominal fullness, early satiation, belching and food 
regurgitation were not. From this study it was concluded that the two-week high dose 
PPI treatment was not effective for early satiation, postprandial abdominal fullness, 
regurgitation or belching symptoms [35]. 
 
 Ford, AC et al (2011); conducted a study about the Rome III criteria .For  in this 
study 1452 adult patients with GI symptoms enrolled  . Individuals with normal upper 
GI endoscopy and histopathology findings from analyses of biopsy specimens were 
classified as having no organic GI disease. This study Concluded that In a validation 
study of 1452 patients with GI symptoms, the Rome III criteria performed for 
identifying and diagnosing functional disorders from other gastrointestinal 
disorder[36]. 
 

 Kei matsueda et al (2011); Conducted a placebo controlled  trial in which 450 
patients with functional dyspepsia  who received  100 mg  acotiamide  and 442 
patients allocated  to placebo three times a day for 4 week. Efficacy of treatment  was 
assessed by overall treatment efficacy (OTE) scale and elimination rate of each three 
meal related symptoms such as Postprandial fullness, Upper abdominal bloating and 
early satiation  were  evaluated. The results supported  that  there is no any 
cardiovascular adverse events, and  a significant improvement in quality of life of FD  
patients. The study found that acotiamide significantly improved symptom severity 
and eliminated meal related symptoms in  patients with FD. [4] 
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
 K. Matsueda et al (2011) ; Performed a  multicenter, open-label, single-arm, long-
term phase III study in which patients with FD  were given acotiamide, 100 mg t.i.d, 
for 48 weeks long-term study of  acotiamide. The study was carried out to investigate 
the efficacy, safety and administration pattern of acotiamide in patients with 
functional dyspepsia (FD). 405 patents were enrolled in this study and the efficacy 
was  analyzed  by OTE improvement rate, the symptom elimination rate increased. 
This study supported that FD symptoms were controlled by intermittent 
administration of acotiamide even in patients with relapsing FD.[2] 
 

 Suzanna Ndraha et al (2011); Carried out a study on 60 dyspeptic patients with 
heartburn and/or regurgitation were enrolled to evaluate the efficacy of combination 
of PPI with prokinetic drug compared to PPI mono therapy in GERD patients with 
high frequency scale for the symptoms of GERD (FSSG) score. They were divided 
into two groups. Group A was given omeprazole 2x20 mg and domperidone 3x10 mg 
for 2 weeks, while another group was only given omeprazole 2x20 mg. The FSSG 
score was performed before treatment and after 2 weeks of treatment. The study 
reveals that combination of omeprazole with domperidone in GERD patients with  
high FSSG score is better than compared to omeprazole monotherapy.[13]. 
 

 Yasuhiro Fujiwara et al (2011); Conducted a study on Japanese workers to identify 
association of cigarette smoking with functional dyspepsia ,GERD or irritable bowel 
syndrome.2680 eligible subjects were enrolled in the study. The results suggest that 
cigarette smoking was a common factor associated with overlaps of FD,GERD or 
irritable bowel syndrome, The association is stronger in smokers who smoked ≥1 
pack per day as compared to those who smoked less than 1 pack per day. This study 
concluded that cigarette smoking was significantly associated with overlaps of 
GERD, FD and IBS among Japanese adults [37]. 
 

 Guilherme Becker Sander et al (2011); Done a study to measure the influence of 
dyspepsia on work productivity of people within the Brazilian workforce.850 adult 
patients were enrolled in the study. All patients answered a demographic 
questionnaire. Productivity impairment was measured by the Work Productivity and 
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Activity Impairment questionnaire. Subjects underwent upper gastrointestinal 
endoscopy and were classified as having functional or organic dyspepsia. The results 
supported  387 (45.5%) were active workers and 78% reported a reduction of the 
work productivity (presenteeism). The affect on work productivity was similar 
between patients with functional or organic dyspepsia. This study showed an 
important influence of dyspepsia on work productivity [38]. 
 

 Jauregui Lobera et al (2011); conducted a study Impact of functional dyspepsia on 
Quality of life in eating disordered patients. 78 patients were enrolled in the study the 
Symptoms of dyspepsia, the related quality of life, anxiety, depression were 
evaluated. The results supported that early satiation and bloating were significantly 
higher in FD Patients. The study concluded that FD constitute a general bias common 
to all eating patients with specific effect on the characteristic symptoms of FD .[39] 
 
 Sheng-Liang Chenloss et al (2010); conducted a study with Eighty-five consecutive 
Chinese patients with FD. This study was to investigate the incidence of nocturnal 
dyspeptic symptoms in patients with functional dyspepsia (FD) and whether 
prokinetic drugs can alleviate them. Baseline nocturnal intragastric pH, bile reflux and 
nocturnal dyspeptic symptoms of eligible patients, including epigastric pain or 
discomfort, abdominal distention and belching, were investigated with questionnaires 
after one year. The result supported that domperidone can alleviate nocturnal 
dyspeptic symptoms,  which may be interrelated with the excessive  nocturnal 
duodenogastric bile reflux.[18]. 
 
 Sanjiv Mahadeva et al (2009); Conducted a study to validate English and locally 
translated version of the Short-Form Nepean Dyspepsia Index (SF-NDI) in Malaysian 
patients who consult for dyspepsia. English and Malay versions of the SF-NDI were 
assessed against the SF-36 and the Leeds Dyspepsia Questionnaire (LDQ), examining 
internal consistency, test-retest reliability and construct validity. 143 patients (86 
English-speaking and 57 Malay speaking) with dyspepsia were enrolled in the study 
and  interviewed them. The results supported that the median total SF-NDI score for 
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both languages were 72.5 and 60.0 respectively. In both languages, SF-NDI sub-
scales and total score demonstrated lower values in patients with more severe 
symptoms and in patients with functional vs organic dyspepsia. This study 
demonstrates that both English and Malay versions of the SF-NDI are reliable and 
probably valid instruments for measuring HRQoL in Malaysian patients with 
dyspepsia [40]. 
 
 Anjiang Wang et al (2008); conducted a study to investigate the prevalence and risk 
factors for overlap of FD and IBS based on Rome III criteria.3014 patients were 
enrolled in study and they were requested to complete the questionnaires. Results 
supported that patients with IBS and FD shows higher severity scores than those with 
FD alone. This study reveals that the common risk factor for clinical overlap of IBS 
and FD is postprandial fullness.[41] 
 

 M.Pajala et al (2006); Performed a study on 400 patients with dyspepsia to evaluate 
assurance of primary care of FD and organic dyspepsia patients and influence of GI 
symptoms and psychological factors by using a completed questionnaire ,and  
monitored  their symptom for one year . The study concluded that the gastrointestinal  
symptoms  for FD is long lasting and investigations shows that patients have lower 
mental distress and fear illness, psychological factors are related to symptoms severity 
changes.[42] 
 

 Sundeep S Shah et al (2001); Conducted a study on prevalence, demography and 
economic implications of dyspepsia in India. 2549 healthy individuals were enrolled 
in the study .gastrointestinal symptoms, their investigations and treatment, dietary 
history and history of addiction were noted. The results showed that 30.4% had 
dyspepsia .33.2 % of patients had dysmotility like dyspepsia which is the most 
common type of dyspepsia. The frequency of dyspepsia was not related to type of diet 
or consumption of spices. Dyspepsia were more prevalent in in subjects who abused 
tobacco or alcohol. This study concluded that dyspepsia occurs in one third of the 
population in Mumbai. Significant symptom occurs in 12%, 40% of peoples were 
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undergone treatment and only a small number undergone endoscopy or 
ultrasonography.[43] 
 

 A L Blum et al (2000); conducted a study to evaluate the treatment of functional 
dyspepsia with acid inhibitors. 792 patients were enrolled in the study. Antacid 
treatment ranitidine 150 mg, omeprazole 10 mg, or omeprazole 20 mg daily. 
Individual dyspeptic and other abdominal symptoms were evaluated before and after 
treatment according to H pylori status. The results supported that there was no 
significant therapeutic gain from active treatment over placebo in H pylori negative 
patients. complete improvement of symptoms and quality of life also occurred most 
frequently with omeprazole 20 mg and was significant in both H pylori positive and H 
pylori negative groups. This study concluded that Omeprazole 20 mg  had  ability to 
disappear most of the symptoms in  H pylori positive patients.[44] 
 

 N.J Talley et al (1998); Performed a study to evaluate the efficacy of proton pump 
inhibitor therapy in functional dyspepsia.1262 patients with a  functional dyspepsia 
(persistent or recurrent epigastric pain or discomfort for at least 1 month and a normal 
upper gastrointestinal endoscopy) were  enrolled and subjected  to receive omeprazole 
20 mg, 10 mg or identical placebo, for 4 weeks. Symptoms were assessed using 
validated measures. Results supported that complete symptom relief was observed in 
38% on omeprazole 20 mg, compared with 36% on omeprazole 10 mg and 28% on 
placebo(P= 0.002 and 0.02, respectively). There was no significant benefit of 
omeprazole over placebo. Symptom relief was similar in H. pylori-positive and 
negative cases. From this study it was concluded that Omeprazole is modestly 
superior to placebo in functional dyspepsia at standard (20 mg) and low doses (10 mg) 
but not in patients with dysmotility-like dyspepsia. [45] 
Kommentar [u1]:  
                                                                                                                             Aim and objective 
 
Department of Pharmacy Practice                                                                                          18 
 
  
 
3. AIM AND OBJECTIVE 
 
AIM 
                 To assess the therapeutic outcome and quality of life of patients with functional 
dyspepsia by treating with proton pump inhibitors, Domperidone and a novel Prokinetic agent 
Acotiamide. 
 
OBJECTIVES  
 To study the prevalence, aetiological factors and characteristics of the functional 
dyspepsia. 
 To identify the treatment options for functional dyspepsia. 
 To measure the outcome of the management. 
 To assess the quality of life. 
 To check adverse drug reaction, if any. 
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4. METHODOLOGY 
STUDY SITE 
            This study was performed in the Department of Gastroenterology, Kovai Medical 
Center and Hospital (KMCH), Coimbatore, Tamil Nadu, India. The proposed protocol for the 
study was presented and approved by the Hospital Ethical committee. 
STUDY TYPE   
              The study was a Prospective observational study on the management of functional 
dyspepsia, to be undertaken at the Department of Gastroenterology, Kovai Medical Centre 
and Hospital (KMCH). 
STUDY DURATION   
The study period was six month. Feb 2018-July.2018. 
STUDY CRITERIA 
  Inclusion criteria: 
             Patients with functional dyspepsia without any metabolic or systemic disease were 
included in the study.  
             Patients having two or more of the following symptoms were included in the study:  
upper abdominal pain, upper abdominal discomfort, postprandial fullness, upper, abdominal 
bloating, early satiation, nausea, vomiting, excessive belching.  
   Exclusion criteria 
 Patients with organic causes of gastroparesis (Eg. Diabetes mellitus) and other 
serious disease (like alcoholism and drug dependence). 
 Pregnant and lactating women. 
 Predominant ulcer like dyspepsia (pain) and symptoms suggestive of irritable bowel 
syndrome. 
 Patient who had undergone any bowel surgery or malignancy.    
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SOURCES OF DATA  
                       Data were collected from Patients case reports and treatment details and direct 
patient interview. Details recorded included patients demographics, social habits, co-
morbidities, medical history, treatment details and outcomes will be noted in a structured 
manner in a data collection form. 
STUDY TOOLS 
 Data collection form 
 Visual Analogue Scale 
 Short-form Nepean Dyspepsia Index  
 SPSS version 20 
 
STUDY PROCEDURE  
                     Patients were divided into three groups. In one group patients were treated with 
PPI a combination of PPI and acotiamide, In the second group patients were treated with 
combination of PPI and domperidone, and in third group patients were treated with PPI alone. 
STUDY POPULATION 
                    A total of 70 patients who fulfill the inclusion criteria included in my study, 10 
patients were excluded by the reason of non complaints. All the 60 patients were enrolled and 
divided into three groups. The patients demographic information, symptoms, treatment 
required for the study were collected using a structured questionnaire and also from different 
data sources available and were recorded in the patient data sheet. Patients characteristics like 
age, gender, smoking status and alcohol intake, food habits, past medical history, treatment 
characteristics were noted.  
                 Visual analogue scale was used to measure the symptom severity, it was a 10-cm 
scale with 0 (no symptom) to 10 (maximum symptom severity) .Visual analogue scale was 
used to measure patients response at the time of enrollment and review after 28 days for the 
symptoms improvement  analysis and then compared.  
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Quality of Life       
                          Nepean dyspepsia index questionnaire is a questionnaire comprising ten item, 
making up five subscales of two items each that examine the impact of dyspepsia on various 
domains of quality of life of patients, including tension/anxiety, disruption of regular eating/ 
drinking. Knowledge and control over disease symptoms and interference with work/study. It 
was used to assess the quality of life of patients with functional dyspepsia with 10 short term 
questionnaire during the enrollment and review after 28 days for quality of life analysis then 
compared. 
STATISTICAL ANALYSIS : 
                       Demographic details and disease treatment characteristics were studied as 
percentages. The difference in the visual analogue scale score between enrollment and review 
was noted. And the difference of Nepean dyspepsia index questionnaire during enrollment 
and review was also noted. The paired ‘t’ test was conducted to analyze the differences of 
both VAS score and quality of life questionnaire score. A p value <0.005 was taken to be 
significant, and there by compare the overall symptom score and questionnaire score for all 
the groups, and to evaluate the efficacy of each therapeutic option. 
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5. TABLES AND GRAPHS 
TABLE.1 AGE WISE DISTRIBUTION AMONG THE STUDY POPULATION (n=60) 
  
 
 
 
 
 
 
 
 
 
Fig.1 AGE WISE DISTRIBUTION AMONG THE STUDY POPULATION (n=60) 
 
  
 
 
AGE 
 
NUMBER OF 
PATIENTS(n=60) 
 
PERCENT (%) 
 
25-34 5 8.3 
35-44 9 15.0 
45-54 24 40.0 
55-64 9 15.0 
65-74 8 13.3 
75-84 5 8.3 
Total 60 100.0 
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TABLE.2 GENDER WISE DISTRIBUTION AMONG THE STUDY POPULATION   
(n=60) 
 
 
 
 
Fig.2 GENDER WISE DISTRIBUTION AMONG THE STUDY POPULATION (n=60) 
 
 
 
 
GENDER NUMBER OF 
PATIENTS(n=60) 
PERCENT (%) 
 
     Male 38 63.3 
     Female 22 36.7 
       Total 60 100.0 
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TABLE 3.DISTRIBUTION OF SMOKING STATUS AMONG THE STUDY 
POPULATION (n=60) 
 
 
 
 
 
 
 
 
Fig.3.DISTRIBUTION OF SMOKING STATUS AMONG THE STUDY 
POPULATION (n=60) 
 
 
  
SMOKING NUMBER OF 
PATIENTS (n=60) 
PERCENT (%) 
 
Past 1 1.7 
Never 59 98.3 
Total 60 100.0 
Tables & Graphs 
 
Department of Pharmacy Practice                                                                                          25 
 
 
 
TABLE.4 DISTRIBUTION OF ALCOHOL INTAKE AMONG THE STUDY 
POPULATION (n=60) 
ALCOHOL NUMBER OF 
PATIENTS (n=60) 
PERCENT (%) 
 
Past 1 1.7 
Present 1 1.7 
Never 58 96.7 
Total 60 100.0 
 
 
Fig.4 DISTRIBUTION OF ALCOHOL INTAKE AMONG THE STUDY 
POPULATION (n=60) 
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TABLE.5 DISTRIBUTION OF FOOD HABITS AMONG THE STUDY 
POPULATION (n=60) 
 
FOOD HABIT NUMBER OF 
PATIENTS (n=60) 
PERCENT (%) 
 
Vegetarians 23 38.3 
Non vegetarians 37 61.7 
Total 60 100.0 
 
 
 
Fig.5.DISTRIBUTION OF FOOD HABITS AMONG THE STUDY POPULATION 
(n=60) 
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TABLE.6 DISTRIBUTION OF BODY WEIGHT AMONG THE STUDY 
POPULATION (n=60) 
 
 
 
WEIGHT(kg) 
 
NUMBER OF 
PATIENTS (n=60) 
 
PERCENT (%) 
 
30-60 28 46.7 
60-80 30 50.0 
80-100 2 3.3 
Total 60 100.0 
 
 
 
Fig.6 DISTRIBUTION OF BODY WEIGHT AMONG THE STUDY POPULATION 
(n=60) 
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TABLE 7.DISTRIBUTION OF DURATION OF SYMPTOMS AMONG THE STUDY 
POPULATION (n=60) 
 
DURATION NUMBER OF 
PATIENTS 
(n=60) 
PERCENT (%) 
 
1 week 5 8.3 
1 month 35 58.3 
2 month 10 16.7 
6 month 7 11.7 
2 month 2 3.3 
3 year 1 1.7 
Total 60 100.0 
 
Fig.7.DISTRIBUTION OF DURATION OF SYMPTOMS AMONG THE STUDY 
POPULATION (n=60) 
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TABLE 8. DISTRIBUTION OF SYMPTOMS AMONG STUDY POPULATION (n=60) 
 
 
 
 
  
 
 
 
 
 
Fig.8 DISTRIBUTION OF SYMPTOMS AMONG STUDY POPULATION (n=60) 
 
 
 
0
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40
Number of patients
SYMPTOMS 
 
NUMBER OF 
PATIENTS (n=60) 
PERCENT (%) 
Postprandial fullness 23 38.3 
Abdominal Discomfort 23 38.3 
Early Satiation 6 10 
Abdominal pain 27 45 
Abdominal Bloating 35 58.3 
Excessive Belching 12 20 
Nausea& Vomiting 14 23.3 
Heart burn 22 36.6 
Tables & Graphs 
 
Department of Pharmacy Practice                                                                                          30 
 
 
TABLE 9.DISTRIBUTION OF NUMBER OF SYMPTOMS AMONG THE STUDY 
POPULATION (n=60) 
 
 
  
 
                          
FIG.9.DISTRIBUTION OF NUMBER OF SYMPTOMS AMONG STUDY  
POPULATION (n=60) 
 
 
 
  
NUMBER OF  
SYMPTOMS 
NUMBER OF 
PATIENTS(n=0) 
PERCENT (%) 
 
1symptom 6 10.0 
2symptoms 21 35.0 
3symptoms 24 40.0 
4symptoms 5 8.3 
5 symptoms 3 5.0 
7symptoms 1 1.7 
TOTAL 60 100.0 
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TABLE 10.VISUAL ANALOGUE   SCALE SCORE OUTCOMES OF 
ACOTIAMIDE+PPI THERAPY BEFORE AND AFTER TREATMENT 
 
Symptoms 
Acotiamide + PPI therapy(n=20) 
Before treatment After treatment p- value 
Mean ±S.D Mean ±S.D 
 
Postprandial fullness 
 
1.20±1.281 
 
0.20±0.410 
 
0.002 
 
Upper abdominal 
discomfort 
0.75±1.333 
 
0.10±.308 0.024 
 
Early satiation 
 
          0.25±0.786 
 
0.00±0.000 
 
0.171 
 
Upper abdominal pain 
 
0.90±1.165 
 
0.30±0.470 
 
0.024 
 
Upper abdominal 
bloating 
1.75±1.251 
 
0.35±.489 0.000 
 
Excessive belching 
1.35±1.424 
 
0.30±.470 
0.001 
 
Nausea& vomiting 
0.35±.875 
         
             0.05±.224 
0.163 
 
Heart burn 
0.90±1.410 
 
0.30±0.470 
0.042 
 
Total score 
 
2.50±0.827 
 
0.7000±0.47016 
 
0.000 
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TABLE 11. SUMMARY OF OVERALL AND SUBSCALE SYMPTOM SCORES ON 
THE SHORT FORM-NEPEAN DYSPEPSIA INDEX(SF-NDI) QUESTIONNAIRE OF 
ACOTIAMIDE THERAPY BEFORE AND AFTER TREATMENT 
Variables Acotiamide +PPI Therapy(n=20) 
 
 
P value 
Before After 
Mean ±S.D Mean ±S.D 
 
Tension 
           
2.00±0.649 
 
1.35±0.489 
 
0.001 
 
Interference with daily 
activities 
 
1.60±0.503 
 
1.20±0.410 
 
0.008 
 
Eating/drinking 
 
1.95±0.224 
 
1.20±0.410 
 
0.000 
 
Knowledge 
 
1.80±0.523 
 
1.25±0.444 
 
0.001 
 
Work/study 
 
2.30±0.470 
 
1.15±0.366 
 
0.000 
 
Total score 
 
2.5500±0.60481 
 
1.0000±0.00000 
 
0.000 
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TABLE 12. VISUAL ANALOGUE SCALE SCORE OUTCOME OF 
PPI+DOMPERIDONE  THERAPY  BEFORE AND AFTER TREATMENT 
 
 
Symptoms 
PPI + Domperidone Therapy(n=60) 
 
Before 
 
After P value 
Mean ±S.D 
 
Mean ±S.D 
Postprandial fullness  
1.10±1.294 
 
0.45±0.686 
 
0.033 
Upper abdominal 
discomfort 
 
1.15±1.348 
 
0.40±0.754 0.005 
Early satiation  
0.25±0.786 
0.05±0.224 
0.297 
Upper abdominal 
pain 
0.90±1.210 0.25±0.550 
0.039 
Upper abdominal 
bloating 
1.80±1.322 1.25±1.209 
0.086 
Excessive belching 0.25±0.786 0.15±0.489 
0.606 
Nausea& vomiting 0.75±1.209 0.65±0.813 
0.733 
Heart burn 1.20±1.281 0.70±0.865 
0.021 
Total score         2.4000±0.99472 2.0000±0.56195 0.042 
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TABLE 13. SUMMARY OF OVERALL AND SUBSCALE SYMPTOM SCORES ON 
THE SHORT FORM- NEPEAN DYSPEPSIA INDEX (SF-NDI) QUESTIONNAIRE 
OF PPI+ DOMPERIDONE BEFORE AND AFTER TREATMENT. 
 
 
 
Variables 
 
PPI+ domperidone therapy(n=20) 
 
 
 
 
 
P- value 
Before 
 
After 
Mean ±S.D 
 
            Mean ±S.D 
 
Tension 
 
1.70±0.657 
 
1.75±0.444 0.772 
Interference with 
daily activities 1.65±0.489 
 
1.95±0.224 0.010 
Eating/drinking 
1.85±0.366 
 
1.95±0.224 0.163 
Knowledge 
1.65±0.489 
 
1.85±0.336 0.042 
Work/study 
1.45±0.686 
 
1.80±0.523 0.031 
Total score 
2.0000±1.07606 
 
1.8000±0.69585 
 
0.428 
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TABLE 14.VISUAL ANALOGUE SCALE OUTCOMES SCORE OF PPI  
MONOTHERAPY BEFORE AND AFTER TREATMENT 
 
 
 
Symptoms 
Proton Pump Inhibitor  Monotherapy (n=20) 
 
 
Before 
 
After 
 
 
P value 
 
Mean± S.D 
 
 
Mean ±S.D 
 
Postprandial fullness 
 
0.65±1.182 
 
0.25±0.786 
0.057 
Upper abdominal 
discomfort 
 
1.10±1.410 
 
0.60±1.095 
0.047 
      
       Early satiation 
           
          0.20±0.616 
 
0.20±.616 0.163 
Upper abdominal pain           1.40±1.465  
0.90±1.165 
0.014 
Upper abdominal 
bloating 
 
0.90±1.294 
0.55±0.999 0.286 
 
Excessive belching 
 
0.50±1.051 
 
0.55±1.146 
0.748 
 
Nausea& vomiting 
 
0.50±1.051 
0.40±.995 0.577 
 
Heart burn 
 
1.05±1.356 
 
0.85±1.226 
0.104 
 
Total score 
 
2.0500±0.60481 
 
2.2000±0.61559 
 
0.330 
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TABLE 15. SUMMARY OF OVERALL AND SUBSCALE SYMPTOM SCORES ON 
THE SHORT FORM-NEPEAN DYSPEPSIA INDEX (SF-NDI) QUESTIONNAIRE OF 
PPI MONOTHERAPY BEFORE AND AFTER TREATMENT 
 
Variables 
 
Proton Pump Inhibitor 
Monotherapy(n=20) 
 
 
P- value 
Before After 
Mean ± S.D Mean ± S.D 
 
Tension 
 
1.35±0.671 
 
1.30±0.733 
0.804 
 
Interference with daily 
activities 
 
1.25±0.099 
 
1.15±0.366 0.163 
 
Eating/drinking 
 
1.45±0.686 
 
1.10±0.069 
0.005 
 
Knowledge 
1.15±0..366 
 
1.15±0.366 
0.000 
 
Work/study 
 
1.40±.681 
 
1.25±0.681 
0.419 
 
Total score 
 
1.7000±0.86450 
 
1.4000±0.608056 
 
0.110 
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                                                     6. RESULTS  
  In this prospective study the management of functional dyspepsia is studied. This 
study is to assess the therapeutic outcome and quality of life of patients with functional 
dyspepsia by treating with Proton Pump Inhibitors, Domperidone and a novel prokinetic 
agent Acotiamide. A total of 70 patients were selected in this study 10 patients were excluded 
since they were non compliant to the treatment. There by 60 patients with functional 
dyspepsia were enrolled, who were attending the Gastroenterology Department of Kovai 
Medical Centre and Hospital during the period of February 2018 to July 2018. Patients were 
divided into three groups. In each group 20 patients were included. In the first group, patients 
who received proton pump inhibitors (PPI) alone were included. In the second group patients 
who undergone PPI and domperidone combination therapy were included. In the third group 
patients who received combination of acotiamide  and PPI were included. 
 The study population was categorized into 6 groups on the basis of age (Table1).24 
patients (40.0%) came under the category of  45 to 54 age group. This indicates that 
incidence of functional dyspepsia is higher in this population. 
 Patients were categorized into 2 groups based on gender. 38 (63.3%) patients were 
coming under the category of male and 22 (36.7%) patients were coming under female 
category. The results show a male predominance for the disease (Table 2). 
 Social habits such as alcohol intake, smoking and food habits also related to 
development of functional dyspepsia. Among the study population (n=60) 96.7 % of patients 
were not alcoholic (Table.4). 98.3% patients not having smoking habits (Table 3). 37 (61.7%) 
patients consumed non vegetarian foods. Only 28 (38.3%) patients consumed vegetarian 
foods. This proves that the people who are consuming non vegetarian foods are more prone to 
functional dyspepsia.(Table 5). 
 In this study 30 (50.0%) of patients came under the category of body weight 60-80 
which indicates more predominance in development of functional dyspepsia.28 (46.7%) of 
patients came under 30-80 and only 2 (3.3) of patients came under 80-100 who are less prone 
to  this disease.(Table 6). 
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 Duration of symptoms occurring as a result of dyspepsia differ in individuals while 35 
(58.3%) had symptom for 1 month 10 (16.7%) patients had symptoms for 2 months,7 
(11.7%) of patients had symptoms for 6 months.5 (8.3%) patients had symptoms for 1 week. 
Only 3.3% and 1.7% of patients had the symptoms for 1 and 2 years. The duration of 
symptoms persist about one month for  most of the patients (Table 7). 
 In this study , 35 (58.3%) of patients had upper abdominal bloating,27 (45%) of 
patients had upper abdominal pain,23 (38.3%) of  patients had postprandial fullness and 
upper abdominal discomfort, 22 (36.6%) of patients had heartburn, only 6(10%) of patients 
had early satiation and 12(20%) of patients had excessive belching,14 (23.3%) of patient had 
nausea and vomiting. Abdominal bloating was showed by most of the patients in this study 
population. (Table 8) 
 The number of symptoms occurring in each individuals were categorized, 24 (40.0%) 
patients had three symptoms, 21 (35%) had two symptoms, 5 (8.3%) patients had four 
symptoms 3 (5%)patients had five symptoms, 6 (10%) patients had one symptom and only 
1(1.7%) patients had 7 symptoms. Most of the patients had three symptoms.(Table 9) 
 Patients were evaluated for the occurance of adverse events caused by treatment 
found among the study population, almost all patient would not had any serious adverse drug 
reaction by the treatments. The adverse drug events were analysed with Naranjo adverse drug 
reaction probability scale (Annexure IV)) 
 By using visual analogue scale (Annexure III), the symptoms of the patients were 
compared before and after the treatment for each group (Group1- PPI, Group2-PPI + 
domperidone, Group3- PPI + acotiamide). The symptoms studied were Postprandial fullness, 
Upper abdominal discomfort, Early satiation, upper abdominal bloating, Upper abdominal 
pain, Excessive belching, Nausea and Vomiting and Heartburn. 
 The individual symptoms were studied for each groups. They were evaluated once 
before the initiation of the therapy and after completion and are shown in (Table 9, 11&13). 
After acotiamide therapy there was significant decrease in postprandial fullness (p=0.002), 
abdominal bloating (p<0.001), upper abdominal discomfort (p=0.024), upper abdominal pain 
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(p=0.024), heart burn (p=0.042), excessive belching (p=0.001). There is significant decrease 
in the total VAS score (p<0.001). 
 In the case of postprandial fullness there is a decrease in the symptom score  in each 
group after treatment. Mean score before acotiamide therapy was 1.20±1.281 and after 
treatment it was 0.20 ± 0.410.  There is significant decrease in the symptom (p=0.002), The 
mean score of symptom before domperidone+PPI therapy was 1.10±1.294 and after treatment 
it is reduced to 0.45 ± 0.686 (p =0.033).  In PPI therapy before treatment the mean score was 
0.65 ± 1.182 and after treatment 0.25 ± 0.786 , there is decrease in symptom mean score (p> 
0.05). 
 For upper abdominal discomfort the mean score before and after therapy was 
0.75±1.333 and 0.10±.308 respectively, there is significant reduction of symptom after 
acotiamide treatment (p=0.024). while the mean score before and after domperidone+PPI  
therapy was  1.15±1.348 and 0.40±0.754 respectively (p=0.005). The mean score of 
symptoms before and after PPI treatment was 1.10±1.410 and 0.60±1.095 respectively 
(p=0.047). Upper abdominal discomfort was reduced significantly after treatment for the 
three treatment. 
 For early satiation the mean score of symptom before acotiamide treatment  was 
0.25±0.786 and  after it was decreased to 0.00±0.000  respectively (p=0.171), For 
domperidone +PPI therapy before treatment and after treatment mean score 0.25±0.786 and 
0.05±0.224 respectively (p=0.297), For PPI treatment before and after symptom score was 
0.05±0.224 and 0.20±0.616  respectively (p=0.163). There is no significant decrease in 
symptom score before and after therapy in three groups. 
 In the case of abdominal pain mean score before acotiamide therapy was 0.30±0.470 
and after therapy it was reduced to 0.90±1.165 (p=0.024) similarly in domperidone therapy 
mean score before and after treatment was 0.25±0.550 and 0.90±1.210 ( p=0.0390) 
respectively. In PPI therapy before symptom mean score was 0.90±1.165 and it was reduced 
to 1.40±1.465 (p=0.014) respectively. There is a significant decrease in the abdominal pain 
for each group. 
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                    For abdominal bloating mean score before acotiamide therapy was 1.75±1.251 
and after treatment it was reduced to 0.35±.489 (p<0.001).There is significant reduction in 
the symptom score. But there is no significant reduction in the symptom score in other 
groups. ((Domperidone  p = 0.086, PPI p= 0.286). 
                    For excessive belching the mean score before and after treatment of acotiamide 
was 1.35±1.424 and 0.30±.470 respectively. (p=0.001) The improvement of symptom scores 
did not differ significantly for other groups. (p= 0.606 for domperidone, p =0.748 for PPI). 
Also there was no any significant improvement of the symptom score for vomiting in three 
groups. 
                       The patient who treated with acotiamide and domperidone shows a significant 
reduction in the symptom heart burn shows (p =0.042 ,p=0.021) difference between before 
and after treatment scores .In PPI therapy there is no significant difference in symptom 
score.( p =0.104). 
                       In overall the total score of the symptom was reduced in acotiamide and 
domperidone therapy. (p<0.001 and 0.042). While in PPI the overall symptom was not 
significantly reduced. 
                       By using Nepean dyspepsia index questionnaire, the quality of life of 
functional dyspepsia patients were compared before and after the therapy between each 
groups (Table 11,13 &15) .Overall SF-NDI score showed a significant greater improvement 
from baseline (p=0.000),  the mean score of overall SF-NDI score before treatment was 
2.5500±0.60481 and after treatment was 1.0000±0.00000. Combination of domperidone and 
PPI and PPI monotherapy did not differ significantly the score  between before and after 
therapy ( p=0.428,p=0.110) 
                      Similarly all the five SF-NDI subscale  scores showed improvement from the 
base line in the acotiamide group compared to other groups.(Tension p= 0.001,interference 
with daily activities p=0.008,eating/drinking p<0.001,knowledge p=0.001,work/study 
p<0.001). 
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                       In group II domperidone therapy there is no significant difference in scores of 
tension, eating/drinking subscale (p=0.772, p=0.163).There is significant improvement in 
knowledge, interference and work/study subscale scores after treatment. 
                     In group1 PPI monotherapy there is significant improvement in the scores of 
knowledge and eating/drinking subscale after therapy (p<0.001, p=0.005).There is no any 
significant improvement in interference (p=0.163), work/study (p=0.419), tension (p=0.804) 
subscales. 
                   By comparing the visual analogue scale score for each group, most of the 
symptoms were improved by acotiamide therapy. There is significant improvement in the 
abdominal bloating, postprandial fullness, abdominal pain, excessive belching , heart burn, 
upper abdominal discomfort. In combination of domperidone and PPI therapy there is 
significant improvement in the symptoms of postprandial fullness, upper abdominal 
discomfort, abdominal pain and heart burn. In PPI monotherapy there is significant reduction 
in the symptoms of postprandial fullness, upper abdominal discomfort and abdominal pain. 
The reduction in the overall symptom score was more in the acotiamide treatment group. 
More symptoms were reduced in acotiamide therapy. 
                 By comparing SF-NDI scores for each groups. A significant reduction in score for 
all  five subscale showed by acotiamide group compared with other groups. By using paired 
‘t’ test, compared the overall symptom score and questionnaire score for each groups. 
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7. DISCUSSION 
                     In this prospective study, out of the total population (n=60), 24 patients 
(40.1%) came under the category of 45-54 years. In a study Varsha Narayanan [46] et 
al., they observed that 60% of the patients were coming under the category of ≥ 40 years 
which indicates higher incidence of functional dyspepsia with age. Suzanna [12], observed 
that 26(43%) of patients had higher incidence of FD in age group of 40-60 years. 
Natasha A. Koloski [47] , observed that mean age of subjects with FGID was 44 yr. This 
proves that there is an association of age with functional dyspepsia. 
                 In this study population, 38(63.3%) were males and 22(36.7%) were females. 
In our study males were found more affected than females. Many studies suggest that the 
incidence of functional dyspepsia is more in females than males. R.H Jones [48] et al., 
observed in a study on dyspepsia in England and Scotland that there is a slight excess of 
female predominance. Roger Jones[49] ,observed in a study of prevalence of functional 
dyspepsia ,that men and women were represented almost equally.  
               R. Bitwayiki [31] et al., studied the prevalence and quality of life of functional 
dyspepsia among Rwandan healthcare workers. In this study smoking, use of alcohol 
were not associated with dyspeptic syndrome. This study shown 39.2% of patients were 
not smokers 41.9% of patients were not alcoholic. In our study 96.7 % of patients were 
not alcoholic and 98.3% of patients were not smokers, which indicates smoking and 
alcohol has not  been shown to be a risk factor in our study. However, Yasuhiro Fujiwara 
[34]
, observed in their study, that smokers were significantly associated with an increased 
FD. 
                 K. Matsueda [2] et al., also observed that 135(33.3%) of patients came under 
body weight of 50-60 subgroup. In our study 30 (50.0%) of patients came under 30-60 
kilogram of body weight which indicates a higher incidence of FD. 
                  The role of food habit had not been well studied probably due to the diversity 
of food habits among the individual populations. Sundeep S Shah [43] et al., observed in 
a study patients symptoms were worsened after taking non vegetarian diet. Spicy foods, 
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fried or food prepared outside the home increases the abdominal fullness. In this study 
the frequency of dyspepsia was not related to the quantity of spices or type of diet 
(vegetarian or non vegetarian) consumed. In our study 38.3% of patients were 
vegetarians and 61.7 % of patients are non vegetarians. This study proves that people 
consuming non vegetarian food are more prone to develop dyspeptic syndromes.  
                   Rocco Maurizio Zagari [50] et al., observed in a study of epidemiology of 
functional dyspepsia and subgroups in the Italian general population, of 114 patients with 
FD 77(67%) had postprandial fullness and early satiation and 55(48.2%) had epigastric 
pain. In our study 35(58.3) of patients had abdominal bloating. Most of the patient had 
abdominal bloating in this study. K.Matsueda [2], observed that among 405 patients 
232(57.3%) had postprandial fullness, 94(23.2%) of patients had bloating and 79(19.5%) 
of patient had early satiation which indicates a predominance in postprandial syndrome 
in most of the patient. 
In our study population, duration of symptoms was different in each individual.  
35(58.3%) of the patients had symptoms for 1 month, 5 (8.3%) of patients had symptoms 
for 1 week, 10(16.7%) of patients had symptoms for 2 months. According to Rome III 
criteria, the symptoms of functional dyspepsia have a history of 3 months. In our study 
the duration of symptoms persist for 1 month probably due to life style modification. Kei 
Matsueda [4]et al., explained that the duration of symptom for most of the patients ≥1 
year.  
                   The overall symptom score for the three groups before and after treatment 
was documented. The overall symptom score and most of the individual symptom score 
was reduced  after the treatment of acotiamide compared to other two groups 
(PPI+domperidone, PPI monotherapy). Kei matsueda[4] et al., observed that the 
symptom score for abdominal bloating, postprandial fullness and early satiation was 
improved in the acotiamide group compared to placebo. The symptom score for nausea 
and vomiting, excessive belching abdominal pain, abdominal discomfort did not differ 
significantly between the groups. In our study there is no  significant reduction in the 
symptom score for early satiation ,nausea and vomiting in the acotiamide group, But had 
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a significant reduction in overall symptom score and individual symptoms such as 
postprandial fullness, abdominal bloating, abdominal pain, upper abdominal discomfort, 
excessive belching, and heartburn. Quality of life of functional dyspepsia patients was 
also studied by kei matsueda [4]. The overall SF-NDI scores showed a significantly 
greater improvement after acotiamide therapy. Similarly all five score showed 
improvement from baseline in the acotiamide group. In our study also there is significant 
improvement in the overall SF-NDI scores and each five SF-NDI subscale scores in the 
acotiamide group. 
              Hiroshi Yamawaki [32] et al, observed in a study acotiamide treatment 
significantly (p=0.007 and p=0.003) improved postprandial fullness and early satiation as 
PDS symptoms in 4 week treatment compared to those pretreatment.  
               Satoshi shinozaki [30] et al., observed that adherence to a therapeutic regimen 
with acotiamide therapy improved long-term outcomes in patients with FD. No adverse 
events occurred throughout the follow up. Long term use of acotiamide is safe and 
effective, and he also observed the efficacy of acotiamide on epigastric syndrome and 
postprandial syndrome in another study. It reveals that acotiamide significantly improves 
the symptoms of EPS as well as PDS at three months. 
               J. Tack [8] et al., observed that long term safety and efficacy of acotiamide in 
functional dyspepsia postprandial distress syndrome. By evaluating overall treatment 
outcome each symptom showed a continuous decrease in score from the baseline. For the 
FD-specific QOL scale SF-NDI the mean value of each domain decreased for all five 
subscale scores. The eating/drinking domain showed largest decrease in score among 
five domains. Our study also revealed the same. 
              In our study by comparing the acotiamide with other two groups, PPI and 
combination of PPI+domperidone groups, acotiamide showed more improvement in the 
symptom score and also quality of life score. Shuhei Mayanagi [33] et al., observed that 
the symptom improved after the combination therapy with PPI and acotiamide than PPI 
monotherapy. 
                            
Discussion 
 
Department of Pharmacy Practice                                                                                                 45 
 
  
 
             K.Y Marakhouski [12] et al., observed in a comparative open label study, 
omeprazole-domperidone combined therapy demonstrates significantly greater efficacy 
than omeprazole alone in the treatment of patients with functional dyspepsia and GERD 
disease. In our study combination of PPI-domperidone combined therapy had 
significantly greater improvement in symptom score and also SF-NDI score for  
knowledge, interference and work/study subscale.       
This study reveals that potent inhibition of acid secretion had a limited role in the 
treatment of FD. In our study PPI significantly reduces the symptom score of upper 
abdominal discomfort and abdominal pain. Based on severity of symptoms, our study 
also found greater improvement with acotiamide therapy compared to PPI monotherapy. 
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8. CONCLUSION 
 Dyspeptic symptoms are defined as the presence of symptoms thought to originate 
from the gastrointestinal region, occurs commonly in the general population. 20-30% of 
the general population are affected by this problem. .Functional dyspepsia is characterized 
by persistent or recurrent epigastric syndromes including postprandial fullness, abdominal 
discomfort, pain, early satiation, bloating, excessive belching, nausea, vomiting and heart 
burn. 
 Our study was focused to assess the therapeutic outcome and quality of life of 
patients with functional dyspepsia by treating with proton pump inhibitors, domperidone 
and a novel prokinetic agent acotiamide. 
 In our study the efficacy of  acotiamide  was evaluated  by comparing with other 
groups of treatment such as PPI monotherapy  and combination of PPI and domperidone. 
The review on patients with FD after one month  showed  a  significant improvement in 
acotiamide therapy and PPI + Domperidone therapy. After treatment analysis, revealed 
more efficacy observed in acotiamide treatment. Similarly SF-NDI score was significantly 
improved in the  acotiamide therapy, All the five domains of SF-NDI were significantly 
improved  after  treatment .          
 Symptoms such as postprandial fullness, abdominal bloating, abdominal pain, 
abdominal discomfort, excessive belching, heartburn were found to be reduced 
significantly in acotiamide therapy, and overall symptom score was also reduced 
significantly. From this study it was concluded that acotiamide has better efficacy than  
PPI monotherapy, and combination of PPI and domperidone. 
           Overall study, enabled us to know the efficacy and safety of acotiamide and there 
by to identify a better treatment option for functional dyspepsia. We believe that our study 
will provide a guidance for developing more appropriate treatment option for functional 
dyspepsia. 
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ANNEXURE II 
DATA COLLECTION FORM 
OP. No.:                                                                 DATE: 
NAME:                  AGE:                                                    SEX: 
WEIGHT:                                       HEIGHT:                                          BMI:                    
ADDRESS: 
OCCUPATION:  
DIET: VEG/ NON-VEG 
SOCIAL HABITS – ALCOHOL                     - present / past / never 
SMOKING/ TOBACCO- present / past / never: 
PAST MEDICAL & MEDICATION HISTORY: 
COMORBIDITIES: 
PRESENT COMPLAINTS: 
Are you treated before for the same complaints: 
If  yes which therapy     : 
 
 
 
 
MEDICATION REGIMEN 
DRUG 
 
DOSE FREQUENCY 
GROUP I 
Proton Pump Inhibitor(PPI) 
  
GROUP II 
Proton Pump 
Inhibitor+Domperidone 
  
GROUP III 
PPI+Acotiamide 
  
 
 
  
SYMPTOM SEVERITY SCALE: 
 
 
 
 
 
 
 
 
 
 
 
Sl. 
No SYMPTOMS 
YES/
NO DURATION 
SEVERITY SCALE  
NONE 
(0) 
MILD 
(1) 
MODERATE 
(2) 
SEVERE 
(3) 
1 Postprandial fullness       
2 Upper abdominal discomfort       
3 Early satiation       
4 Upper abdominal pain       
5 Upper abdominal bloating       
6 Excessive belching       
7 Nausea& vomiting       
8 Heartburn       
ANNEXURE III 
     VISUAL ANALOG SCALE (VAS) 
 
Postprandial fullness:  
                                                                 
NONE                              WORST 
 
Upper abdominal discomfort 
 
   NONE                                                                                                        WORST 
 
Early satiation 
 
  NONE                                                                                                        WORST 
Upper abdominal pain: 
 
   NONE                                                                                                        WORST 
Upper abdominal bloating: 
  
   NONE                                                                                                        WORST 
 
Excessive belching: 
 
   NONE                                                                                                        WORST 
 
Nausea& vomiting: 
 
   NONE                                                                                                        WORST 
Heartburn: 
 
    NONE                                                                                                       WORST                                  
  
 
  
                                                            ANNEXURE IV 
NARANJO ADVERSE DRUG REACTION PROBABILITY SCALE 
Modified from:Naranjo C A et al.Amethod for estimating the probability of adverse drug reactions.Clin 
Pharmacol Ther 1981;30:239-245. 
 
NARANJO ADVERSE DRUG REACTION PROBABILITY SCALE 
Sl. 
No Question Yes No 
Do 
Not 
Know 
Score 
1 Are there previous conclusive reports on this reaction? +1 0 0 
 
2 Did the adverse event appear after the suspected drug 
was administered? +2 -1 0  
3 Did the adverse reaction improve when the drug was 
discontinued or a specific antagonist was 
administered? 
+1 0 0 
 
4 Did the adverse event reappear when the drug was re-
administered? +2 -1 0  
5 Are there alternative causes (other than the drug) that 
could on their own how caused the reaction?  -1 +2 0  
6 Did the reaction reappeared when a placebo was 
given? -1 +1 0  
7 Was the drug detected in blood (or other fluid) in 
concentrations known to be toxic? +1 0 0  
8 Was the drug more severe when the dose was 
increased or less severe when the dose was decreased? +1 0 0  
9 Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure? +1 0 0  
10 Was the adverse event confirmed by any objective 
evidence? +1 0 0  
 
 Total Score 
 
ANNEXURE V 
SHORT FORM DYSPEPSIA INDEX QUESTIONNAIRE (SF-NDI) 
              Circle the number of the response that best describes how you have been. Each item 
is scored on a five-point Likert scale (1 = not at all, 2 = a little, 3 = moderately, 4 = quite a 
lot, and 5 = extremely), 
Tension 
1. Has your general emotional well-being been disturbed by your stomach problems in the 
last 2 
    weeks? 
1. 1. Not at all. 
1. 2. A little. 
1. 3. Moderately. 
1. 4. Quite a lot. 
1. 5. Extremely. 
2. Have you been irritable, tense or frustrated in the last 2 weeks because of your stomach  
    problems? 
2. 1. Not at all. 
2. 2. A little. 
2. 3. Moderately. 
2. 4. Quite a lot. 
2. 5. Extremely. 
Interference with daily activities 
3. Has your ability to engage in things you usually dofor fun (recreations, going out, hobbies,     
    sports, etc.) been disturbed by your stomach problems in the last 2 weeks? 
3. 1. Not at all. 
3. 2. A little. 
3. 3. Moderately. 
3. 4. Quite a lot. 
3. 5. Extremely. 
 
4. Has your enjoyment of things you usually do for fun (recreations, going out, hobbies,  
    sports,  etc.) been disturbed by your stomach problems in the last 2 weeks? 
4. 1. Not at all. 
4. 2. A little. 
4. 3. Moderately. 
4. 4. Quite a lot. 
4. 5. Extremely. 
Not applicable (I have not been able to do any of these things in the past 2 weeks) 
Eating/drinking 
5. Has your ability to eat or drink (including when,what, and how much) been disturbed by  
     your  stomach problems in the last 2 weeks? 
5. 1. Not at all. 
5. 2. A little. 
5. 3. Moderately. 
5. 4. Quite a lot. 
5. 5. Extremel 
6. Has your enjoyment of eating and/or drinking been disturbed by your stomach problems in     
    the last 2 weeks? (Please also include your appetite, and how you feel after food or drink). 
6. 1. Not at all. 
6. 2. A little. 
6. 3. Moderately. 
6. 4. Quite a lot. 
6. 5. Extremely. 
Knowledge/control 
7. Have you wondered whether you will always have these stomach problems, in the last 2  
    weeks? 
7. 1. Almost never. 
7. 2. Sometimes. 
7. 3. Fairly often. 
7. 4. Very often. 
7. 5. always.  
 
8. Have you thought that your stomach problems might be due to a very serious illness (e.g.  
    cancer or a heart problem), in the last 2 weeks? 
8. 1. Almost never. 
8. 2. Sometimes. 
8. 3. Fairly often. 
8. 4. Very often. 
8. 5. always. 
  Work/study 
9. Has your ability to work or study been disturbed by your stomach problems in the last 2  
    weeks? 
9. 1. Not at all. 
 . 2. A little. 
9. 3. Moderately. 
9. 4. Quite a lot. 
9. 5. Extremely. 
6. Not applicable (I do not work or study). 
10. Has your enjoyment of work or study been disturbed by your stomach problems in the  
      last 2 weeks? 
10. 1. Not at all. 
10. 2. A little. 
10. 3. Moderately. 
10. 4. Quite a lot. 
10. 5. Extremely. 
10. Not applicable (I have not worked or studied in the last 2 weeks). 
